Velcade (Bortezomib) (Millennium: The Takeda Oncology Company) for mantle cell lymphoma

Record ID 32010000983
Authors' objectives:

Mantle cell lymphoma (MCL) is a distinct subtype of B-cell non-Hodgkin's lymphoma (NHL). Although the cancer begins in the mantle zone, the lymphoma cells can accumulate, enter the lymphatic system and the blood, and spread to other lymph nodes or tissues such as the spleen, liver, bone marrow, and gastrointestinal tract. Patients with MCL are typically older adults, predominately male, and present with advanced-stage disease. Approximately 65,980 people will be diagnosed with NHL in 2009, and MCL accounts for 5% to 8% of all NHL cases. Although MCL often responds to initial treatment, it is associated with a high relapse rate. In the relapsed and refractory states, partial responses to treatment and a short duration of benefit are common. MCL patients generally have a poor prognosis with a median overall survival of 3 to 4 years from diagnosis. There is no consensus for the treatment of patients with MCL, and it is considered an incurable disease.

Project Status: Completed
URL for project:
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Antineoplastic Agents
  • Lymphoma, Mantle-Cell
  • Pyrazines
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
Contact Email:
Copyright: 2010 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.